Measles
Savvy Senior: Recommended Vaccines For Medicare Recipients
Dear Savvy Senior,
My husband and I recently turned 65 and would like to find out which vaccines are recommended and covered by Medicare?
New Beneficiaries
All recommended vaccines for adults, age 65 and older, should be covered by either Medicare Part B or Part D, but there are some coverage challenges you should be aware of. Here's a rundown of which vaccines are recommended by the Centers for Disease Control and Prevention and how Medicare covers them.
COVID-19: Even though COVID-19 is no longer a public health emergency, it can still cause severe illness, particularly in older adults. Because the COVID virus continues to mutate, new vaccines are being developed to keep pace, so the CDC recommends that all seniors stay up to date with the latest COVID vaccines, including booster shots.
All COVID-19 shots are covered 100% by Medicare Part B.
Flu: Considered an annual vaccination, most people of all ages receive flu shots in the fall when flu season begins. The CDC recommends seniors, 65 and older, get a high-dose flu shot for extra protection beyond what a standard flu shot offers. The Fluzone High Dose Quadrivalent, FLUAD Quadrivalent and FluBlok Quadrivalent are your three options.
Annual flu shots are covered under Medicare Part B.
Pneumonia: These vaccines help protect against pneumococcal disease, which can cause pneumonia, meningitis and other infections. The CDC recommends everyone 65 and older get a pneumococcal vaccine. There are several different vaccine options available, so talk to your doctor or pharmacists to find out which is best for you or visit the CDC's Pneumococcal Vaccination webpage at CDC.Gov/vaccines/vpd/pneumo/public/index.Html.
Medicare Part B covers both single dose and two-dose pneumococcal shots once in your lifetime.
Shingles: Caused by the same virus that causes chicken pox, shingles is a painful, blistering skin rash that affects more than 1 million Americans every year. All people over age 50 are recommended to get the two-dose Shingrix vaccine, which is given two to six months apart, even if you previously received Zostavax. In 2020, Shingrix replaced Zostavax, which is no longer available in the U.S.
All Medicare Part D prescription drug plans cover shingles vaccinations, but coverage amounts, and reimbursement rules vary depending on where the shot is given. Check your plan.
Tdap: Tetanus, diphtheria and pertussis (whooping cough) are diseases caused by bacteria that can lead to serious illness and death. Therefore, a one-time dose of the Tdap vaccine is recommended to all adults. If you've already had a Tdap shot, you should get a tetanus-diphtheria (Td) booster shot every 10 years.
All Medicare Part D plans cover these vaccinations.
RSV: Respiratory syncytial virus, or RSV, can lead to pneumonia or bronchiolitis and can worsen other chronic conditions common among older adults, such as asthma and chronic obstructive pulmonary disease. The CDC recommends all adults — age 60 and older — talk to their doctor about getting one of the RSV vaccines (either Arexvy or Abrysvo), usually in the fall and winter months when the virus is most prevalent.
Most Medicare Part D plans cover the RSV vaccine, but not all. If your plan doesn't cover it, you can ask for a coverage exception. You can also pay for the shot out of pocket and then follow up with your plan to get reimbursed. If you pay for the shot upfront, your plan must pay you back.
Other vaccinationsThere are other vaccines you may need depending on your health, lifestyle or travel plans. To help you get a handle on which ones are appropriate for you, take the CDC's What Vaccines Do You Need? Quiz at www2.Cdc.Gov/nip/adultimmsched. Also, talk to your doctor during your next visit about what vaccinations you should get.
Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.Org. Jim Miller is a contributor to the NBC "Today" show and author of "The Savvy Senior" book.
Global Pneumococcal Vaccines Market To Witness Steady Growth, Projected To Surpass US$ 13.3 Billion By 2033
Pneumococcal Vaccines Market The global pneumococcal vaccines market is poised to exhibit steady growth, with an anticipated Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period. According to the latest insights from Future Market Insights, the market's valuation reached US$ 8.9 Billion in 2023, and it is expected to surpass US$ 13.3 Billion by 2033.
Analysts at Future Market Insights have recorded a historical market valuation of US$ 8.5 Billion for the pneumococcal vaccines market during the base year, underlining the sector's sustained growth trajectory.
Request For A Sample: https://www.Futuremarketinsights.Com/reports/sample/rep-gb-7078
Pneumococcal vaccines play a crucial role in preventing diseases caused by Streptococcus pneumoniae bacteria, including pneumonia, meningitis, and bloodstream infections. With increasing awareness about the importance of vaccination and rising initiatives by healthcare organizations worldwide, the demand for pneumococcal vaccines is anticipated to witness significant growth over the forecast period.
Key factors contributing to the market's growth include advancements in vaccine development technologies, expanding immunization programs, and rising investments in healthcare infrastructure. Additionally, the growing prevalence of pneumococcal infections, particularly among children and the elderly, underscores the urgent need for effective vaccination strategies.
The projected growth of the pneumococcal vaccines market signifies opportunities for stakeholders, including vaccine manufacturers, healthcare providers, and policymakers, to collaborate and address the global burden of pneumococcal diseases.
The factors supporting the growth of the pneumococcal vaccines industry is spot on. Here's a breakdown of why each element contributes:
Overall, these factors create a positive outlook for the pneumococcal vaccines industry, with a projected growth in the coming years.
Customization Available Request: https://www.Futuremarketinsights.Com/customization-available/rep-gb-7078
Key Takeaways from the Pneumococcal Vaccines Market:
Competitive Landscape:
Leading Industry Players Illuminate Opportunities Amidst Technological Advancements The pneumococcal vaccines market thrives in its diversity, as major manufacturers employ a variety of strategies to stay ahead of the competition. Through both organic growth and strategic acquisitions, industry giants are investing heavily in research and development to enhance the efficacy of pneumococcal vaccines, particularly in addressing chronic illnesses prevalent among aging populations.
Activirosomes, for instance, pioneers the development of viral infection vaccines. Harnessing active virosome technology, the company engineers non-replicating derivatives of measles and other viruses, focusing solely on essential viral genes that trigger robust immune responses.
Recent Developments:
Some of the key players proliferating in the market are:
Request Purchase Now: https://www.Futuremarketinsights.Com/checkout/7078
Key Segments in the Pneumococcal Vaccines Market:
By Product Type:
By Distribution Channel:
By Region:
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Navigating Vaccine Coverage For Seniors With Medicare Changes
What You Need to KnowGetting the right vaccinations can help your older clients stay healthy and active longer.
As individuals age, their need for protective measures against certain infectious diseases, including shingles and respiratory syncytial virus , major cause of pneumonia, becomes increasingly important.
George, a 70-year-old retired social worker, sent us a question about this topic.
The QuestionUnder the Inflation Reduction Act, are vaccines like the shingles vaccine now covered by Medicare at no cost? If so, how can I get them?
The AnswerYes, the Inflation Reduction Act helped Medicare beneficiaries by providing coverage of eligible vaccines with no out-of-pocket costs for the beneficiaries. The list of covered vaccines includes the vaccines against shingles, RSV and pneumonia.
This legislative change marks an important shift toward enhancing preventive health measures for seniors, promoting a proactive approach to health care.
Which Plan Covers WhatThrough Original Medicare, Part B provides shots for seasonal flu, pneumonia and COVID-19; as well as hepatitis B vaccines for high-risk individuals, plus tetanus shots for beneficiaries who are injured.
Medicare Part D prescription drug plans cover the shingles, Tdap, RSV, hepatitis and meningococcal vaccines.
For those with Medicare Advantage plans that encompass prescription drug coverage, the same protections apply.
More to ConsiderCovered vaccines: The Inflation Reduction Act offers certain recommended preventive vaccines free of charge for those beneficiaries enrolled in a Medicare Part D plan.
Comments
Post a Comment